Gregory Thomas Kennedy

Gregory Thomas Kennedy

Auto-generated profile, based on publicly available information

Gregory Thomas Kennedy

Department of Surgery, University of Pennsylvania School of Medicine, Philadelphia, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 July 2022 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
GKGregory T. Kennedy
Gregory T. Kennedy
DHDavid E. Holt
David E. Holt
FAFeredun S. Azari
Feredun S. Azari
EBElizabeth Bernstein
Elizabeth Bernstein
BNBilal Nadeem
Bilal Nadeem
SSSunil Singhal
Sunil Singhal
Purpose: Fluorescence-guided surgery using tumor-targeted contrast agents has been developed to improve the completeness of oncologic resections. Quenched activity–based probes that fluoresce after covalently binding to tumor-specific enzymes have been proposed to improve specificity, but none have been tested in humans. Here, we report the successful clinical translation of a cathepsin activity–based probe (VGT-309) for fluorescence-guided surgery. Experimental Design: We optimized the specificity, dosing, and timing of VGT-309 in preclinical models of lung cancer. To evaluate clinical feasibility, we conducted a canine study of VGT-309 during pulmonary tumor resection. We then conducted a randomized, double-blind, dose-escalation study in healthy human volunteers receiving VGT-309 to evaluate safety. Finally, we tested VGT-309 in humans undergoing lung cancer surgery. Results: In preclinical models, we found highly specific tumor cell labeling that was blocked by a broad spectrum cathepsin inhibitor. When evaluating VGT-309 for guidance during resection of canine tumors, we found that the probe selectively labeled tumors and demonstrated high tumor-to-background ratio (TBR; range: 2.15–3.71). In the Phase I human study, we found that VGT-309 was safe at all doses studied. In the ongoing Phase II trial, we report two cases in which VGT-309 localized visually occult, non-palpable tumors (TBRs = 2.83 and 7.18) in real time to illustrate its successful clinical translation and potential to improve surgical management. Conclusions: This first-in-human study demonstrates the safety and feasibility of VGT-309 to label human pulmonary tumors during resection. These results may be generalizable to other cancers due to cathepsin overexpression in many solid tumors.

1 May 2023 in Journal of Biomedical Optics
Verified
Journal Article
Open access
PDF file
PBPatrick Bou-Samra
Patrick Bou-Samra
NMNajib Muhammad
Najib Muhammad
ACAustin Chang
Austin Chang
RKRitesh Karsalia
Ritesh Karsalia
FAFeredun Azari
Feredun Azari
SSSunil Singhal
Sunil Singhal
According to the World Health Organization, there were almost 18 million patients living with cancer in 2020. It is estimated that over 14 million patients will require oncologic surgery in 2040. This is a 52% increase from 2018 estimations.1 Due to the importance of a complete (R0) resection on survival and the increase in detection of early-stage disease, surgical resection remains an important treatment of solid tumors.2,3 Achieving an R0 resection and identifying disease in lymph nodes or synchronous lesions has been shown repeatedly to improve oncologic outcomes and is a mainstay of curative-intent treatment.4 However, achieving these margins and finding residual disease during surgery remains a challenge for surgical oncologists. This is mainly due to the inability to see microscopic disease left behind and, at times, uncertainty about involvement of vital structures.

17 May 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
GKGregory T. Kennedy
Gregory T. Kennedy
FAFeredun S. Azari
Feredun S. Azari
EBElizabeth Bernstein
Elizabeth Bernstein
BNBilal Nadeem
Bilal Nadeem
ACAshley Chang
Ashley Chang
SSSunil Singhal
Sunil Singhal
Suspicious nodules detected by radiography are often investigated by biopsy, but the diagnostic yield of biopsies of small nodules is poor. Here we report a method—NIR-nCLE—to detect cancer at the cellular level in real-time during biopsy. This technology integrates a cancer-targeted near-infrared (NIR) tracer with a needle-based confocal laser endomicroscopy (nCLE) system modified to detect NIR signal. We develop and test NIR-nCLE in preclinical models of pulmonary nodule biopsy including human specimens. We find that the technology has the resolution to identify a single cancer cell among normal fibroblast cells when co-cultured at a ratio of 1:1000, and can detect cancer cells in human tumors less than 2 cm in diameter. The NIR-nCLE technology rapidly delivers images that permit accurate discrimination between tumor and normal tissue by non-experts. This proof-of-concept study analyzes pulmonary nodules as a test case, but the results may be generalizable to other malignancies.

11 February 2022 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
GKGregory T. Kennedy
Gregory T. Kennedy
FAFeredun S. Azari
Feredun S. Azari
EBElizabeth Bernstein
Elizabeth Bernstein
BNBilal Nadeem
Bilal Nadeem
ACAshley E. Chang
Ashley E. Chang
SSSunil Singhal
Sunil Singhal
Pulmonary squamous cell carcinoma is the second most common lung cancer subtype and has a low 5-year survival rate at 17.6%. Complete resection with negative margins can be curative, but a high number of patients suffer early postoperative recurrence due to inadequate disease clearance at the index operation. Intraoperative molecular imaging (IMI) with tumor-targeted optical contrast agents is effective in improving resection completeness for other tumor types, but there are no IMI tracers targeted to pulmonary squamous cell carcinoma. In this report, we describe the use of a novel prostate-specific membrane antigen (PSMA)-targeted near-infrared conjugate (OTL78) to identify pulmonary squamous cell carcinoma. We identified PSMA as a viable target by examining its expression in human lung tumor specimens from a surgical cohort. Ninety-four percent of tumors expressed PSMA in either the pulmonary squamous cells or the tumor neovasculature. Using in vitro and in vivo models, we found that OTL78 reliably localized pulmonary squamous cell carcinoma in a PSMA-dependent manner. Finally, we found that IMI with OTL78 markedly improved surgeons' ability to identify residual disease after surgery in a preclinical model. Ultimately, this novel optical tracer may aid surgical resection of pulmonary squamous cell carcinoma and potentially improve long-term outcomes.

11 July 2024 in Molecular Imaging and Biology
Verified
Journal Article
Closed access
PDF file
GKGregory T. Kennedy
Gregory T. Kennedy
FAFeredun S. Azari
Feredun S. Azari
ACAustin Chang
Austin Chang
PBPatrick Bou-Samra
Patrick Bou-Samra
CDCharuhas Desphande
Charuhas Desphande
SSSunil Singhal
Sunil Singhal

14 July 2022 in Molecular Imaging
Verified
Journal Article
Open access
PDF file
GKGregory T. Kennedy
Gregory T. Kennedy
FAFeredun S. Azari
Feredun S. Azari
BNBilal Nadeem
Bilal Nadeem
ACAshley Chang
Ashley Chang
ASAlix Segil
Alix Segil
SSSunil Singhal
Sunil Singhal
Background. Early detection and complete resection are important prognostic factors for esophageal cancer (EC). Intraoperative molecular imaging (IMI) using tumor-targeted tracers is effective in many cancer types. However, there are no EC-specific IMI tracers. We sought to test a cathepsin activity-based tracer (VGT-309) for EC resection. Methods. Murine (AKR, HNM007) and human (OE19) EC cell lines were screened for cathepsin expression by western blotting. In vitro binding affinity of VGT-309 was evaluated by fluorescence microscopy. Flank tumor models were developed by injecting EC cells into the flanks of BALB/c or athymic nude mice. Mice pretreated with a cathepsin inhibitor (JPM-OEt) were used to confirm on target binding. Animals were injected with 2mg/kg VGT-309, underwent IMI, and were sacrificed 24 hours after injection. Results. Cathepsins B, L, S, and X were expressed by EC cell lines, and all cell lines were labeled in vitro with VGT-309. Fluorescent signal was eliminated when cells were pretreated with JPM-OEt. On biodistribution analysis, VGT-309 accumulated in the liver, kidneys, and spleen without other organ involvement. VGT-309 selectively accumulated in flank allografts and xenografts, with mean signal-to-background ratio of 5.21 (IQR: 4.18-6.73) for flank allografts and 4.34 (IQR: 3.75-5.02) for flank xenografts. Fluorescence microscopy and histopathological analysis confirmed the selective accumulation of the tracer in tumors compared to background normal tissues. Conclusions. VGT-309 is an effective tracer for IMI of esophageal cancer. There is potential for clinical translation both as an adjunct to endoscopic detection and for complete removal of disease during esophagectomy.